GT
LFCR icon

Glenmede Trust’s Lifecore Biomedical LFCR Stock Holding History

Glenmede Trust’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,807
Closed -$131K – 2307
2013
Q3 		$131K Buy
+10,807
New +$151K ﹤0.01% 1281

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Glenmede Trust's LFCR Position: Q4 2013 in Review

Glenmede Trust sold out of Lifecore Biomedical (LFCR) in Q4 2013, closing a stake of 10,807 shares — an estimated $131K sold.

Glenmede Trust first reported a position in LFCR in Q3 2013 and held it in 1 quarter. The position peaked at $131K in Q3 2013. 111 funds tracked by Wall St. Rank hold LFCR as of Q4 2013.

  • Glenmede Trust reported no remaining Lifecore Biomedical position as of Q4 2013 after selling out during the quarter.
  • Glenmede Trust sold 10,807 Lifecore Biomedical shares in Q4 2013, an estimated $131K.
  • Glenmede Trust first reported a position in Lifecore Biomedical in Q3 2013 and held it in 1 quarter.
  • Glenmede Trust's Lifecore Biomedical position peaked at $131K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2013.

Based on Glenmede Trust's 13F filing for Q4 2013, filed 31 Jan 2014.